PDF herunterladen
Pharmacopsychiatry 2021; 54(06): 279-286
DOI: 10.1055/a-1525-2820
Original Paper

Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study

Céline Dubath
1   Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
,
Marianna Piras
1   Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
,
Mehdi Gholam
2   Center for Psychiatric Epidemiology and Psychopathology, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
,
Nermine Laaboub
1   Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
,
Claire Grosu
1   Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
,
Othman Sentissi
3   Adult Psychiatry Division, Department of Psychiatry, University Hospital of Geneva, Geneva, Switzerland
,
Franziska Gamma
4   Les Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland
,
Alessandra Solida
5   Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
,
Armin von Gunten
6   Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
,
Philippe Conus
5   Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
,
Chin B. Eap
1   Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
7   School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
8   Center for Research and Innovation in Clinical Pharmaceutical Sciences, University of Lausanne, Lausanne, Switzerland
9   Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland
› Institutsangaben Funding: This work was supported in part by the Swiss National Research Foundation (CE and PC: 320030–120686, 324730–144064, 320030–173211; CE, PC and KP: 320030-200602). The funding sources had no role in the writing of the manuscript or in the decision to submit it for publication.
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Introduction The atypical antipsychotic quetiapine is known to induce weight gain and other metabolic complications. The underlying mechanisms are multifactorial and poorly understood with almost no information on the effect of dosage. Concerns were thus raised with the rise in low-dose quetiapine off-label prescription (i. e.,<150 mg/day).

Methods In this study, we evaluated the influence of quetiapine dose for 474 patients included in PsyMetab and PsyClin studies on weight and metabolic parameter evolution. Weight, blood pressure, lipid, and glucose profiles were evaluated during a follow-up period of 3 months after treatment initiation.

Results Significant dose-dependent metabolic alterations were observed. The daily dose was found to influence weight gain and increase the risk of undergoing clinically relevant weight gain (≥7% from baseline). It was also associated with a change in plasma levels of cholesterol (total cholesterol, LDL cholesterol, and HDL cholesterol) as well as with increased odds of developing hypertriglyceridemia, as well as total and LDL hypercholesterolemia. No impact of a dose increase on blood pressure and plasma glucose level was observed.

Discussion The dose-dependent effect highlighted for weight gain and lipid alterations emphasizes the importance of prescribing the minimal effective dose. However, as the effect size of a dose increase on metabolic worsening is low, the potential harm of low-dose quetiapine should not be dismissed. Prescriptions must be carefully evaluated and regularly questioned in light of side effect onset.

Key words

antipsychotic drugs - off-label prescription - safety profile - cardio-metabolic health - dose-dependent side effect

Supplementary Material



Publikationsverlauf

Eingereicht: 05. Januar 2021

Angenommen: 21. April 2021

Artikel online veröffentlicht:
13. August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Correll CU, Solmi M, Veronese N. et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113, 383, 368 controls. World Psychiatry 2017; 16: 163-180
    CrossrefPubMedGoogle Scholar
  • 2 Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis. JAMA Psychiatry 2015; 72: 334-341
    CrossrefPubMedGoogle Scholar
  • 3 Tek C, Kucukgoncu S, Guloksuz S. et al. Antipsychotic-induced weight gain in first-episode psychosis patients: A meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry 2016; 10: 193-202
    CrossrefPubMedGoogle Scholar
  • 4 Barton BB, Segger F, Fischer K. et al. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf 2020; 19: 295-314
    CrossrefPubMedGoogle Scholar
  • 5 Musil R, Obermeier M, Russ P. et al. Weight gain and antipsychotics: A drug safety review. Expert Opin Drug Saf 2015; 14: 73-96
    CrossrefPubMedGoogle Scholar
  • 6 Burghardt KJ, Seyoum B, Mallisho A. et al. Atypical antipsychotics, insulin resistance and weight; A meta-analysis of healthy volunteer studies. Prog Neuropsychopharmacol Biol Psychiatry 2018; 83: 55-63
    CrossrefPubMedGoogle Scholar
  • 7 Abosi O, Lopes S, Schmitz S. et al. Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig 2018; 36: j/hmbci.2018.36.issue-1/hmbci-2017-0065/hmbci-2017-0065.xml doi:10.1515/hmbci-2017-0065
    PubMed
  • 8 Singh R, Bansal Y, Medhi B. et al. Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol 2019; 844: 231-240
    CrossrefPubMedGoogle Scholar
  • 9 Marteene W, Winckel K, Hollingworth S. et al. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf 2019; 18: 1149-1160
    CrossrefPubMedGoogle Scholar
  • 10 Gierisch JM, Nieuwsma JA, Bradford DW. et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: A systematic review and meta-analysis. J Clin Psychiatry 2014; 75: e424-e440
    CrossrefPubMedGoogle Scholar
  • 11 Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009; 70: 1041-1050
    CrossrefPubMedGoogle Scholar
  • 12 Maher AR, Maglione M, Bagley S. et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. J Am Med Assoc 2011; 306: 1359-1369
    CrossrefPubMedGoogle Scholar
  • 13 Citrome L, Jaffe A, Levine J. et al. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry 2005; 66: 1512-1516
    CrossrefPubMedGoogle Scholar
  • 14 Lee TC, Desforges P, Murray J. et al. Off-label use of quetiapine in medical inpatients and postdischarge. JAMA Intern Med 2016; 176: 1390-1391
    CrossrefPubMedGoogle Scholar
  • 15 Duncan D, Cooke L, Symonds C. et al. Quetiapine use in adults in the community: A population-based study in Alberta, Canada. BMJ Open 2016; 6: e010861-e010861
    CrossrefPubMedGoogle Scholar
  • 16 Morrens M, Destoop M, Cleymans S. et al. Evolution of first-generation and second-generation antipsychotic prescribing patterns in Belgium between 1997 and 2012: A population-based study. J Psychiatr Pract 2015; 21: 248-258
    CrossrefPubMedGoogle Scholar
  • 17 Marston L, Nazareth I, Petersen I. et al. Prescribing of antipsychotics in UK primary care: A cohort study. BMJ Open 2014; 4: e006135
    CrossrefPubMedGoogle Scholar
  • 18 Gao K, Kemp DE, Fein E. et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011; 72: 1063-1071
    CrossrefPubMedGoogle Scholar
  • 19 Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother 2012; 46: 718-722
    CrossrefPubMedGoogle Scholar
  • 20 Carr CN, Lopchuk S, Beckman ME. et al. Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review. Ment Health Clin 2016; 6: 308-313
    CrossrefPubMedGoogle Scholar
  • 21 Honer WG, MacEwan GW, Gendron A. et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012; 73: 13-20
    CrossrefPubMedGoogle Scholar
  • 22 Bazo-Alvarez JC, Morris TP, Carpenter JR. et al. Effects of long-term antipsychotics treatment on body weight: A population-based cohort study. J Psychopharmacol 2020; 34: 79-85
    CrossrefPubMedGoogle Scholar
  • 23 Dubath C, Delacretaz A, Glatard A. et al. Evaluation of cardiometabolic risk in a large psychiatric cohort and comparison with a population-based sample in Switzerland. J Clin Psychiatry 2020; 81
    PubMedGoogle Scholar
  • 24 Choong E, Solida A, Lechaire C. et al. Suivi du syndrome métabolique induit par les antipsychotiques atypiques: Recommandations et perspectives pharmacogénétiques. Rev Med Suisse 2008; 4: 1994-1999
    PubMedGoogle Scholar
  • 25 Alberti KG, Zimmet PZ, Shaw J et al. IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, Belgium: International Diabetes Federation; 2006
    Google Scholar
  • 26 AstraZeneca. Seroquel (quetiapine fumarate)—FDA. FDA; 1997
    Google Scholar
  • 27 Vandenberghe F, Gholam-Rezaee M, Saigi-Morgui N. et al. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 2015; 76: e1417-e1423
    CrossrefPubMedGoogle Scholar
  • 28 Delacretaz A, Vandenberghe F, Gholam-Rezaee M. et al. Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and new onset dyslipidemia. J Clin Lipidol 2018; 12: 219-229. DOI: 10.1016/j.jacl.2017.10.002.
    CrossrefPubMedGoogle Scholar
  • 29 Grajales D, Ferreira V, Valverde ÁM. Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain. Cells 2019; 8: 1336
    CrossrefPubMedGoogle Scholar
  • 30 Aichhorn W, Marksteiner J, Walch T. et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006; 21: 81-85
    CrossrefPubMedGoogle Scholar
  • 31 Albantakis L, Egberts K, Burger R. et al. Relationship between daily dose, serum concentration, and clinical response to quetiapine in children and adolescents with psychotic and mood disorders. Pharmacopsychiatry 2017; 50: 248-255
    Artikel in Thieme ConnectPubMedGoogle Scholar